Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of March 31, 2025, Alexandria has a total market capitalization of $28.8 billion and an asset base in North America that includes 39.6 million RSF of operating properties and 4.0 million RSF of Class A/A+ properties undergoing construction. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Megacampus environments that enhance our tenants' ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.
Life Sciences Leade | Alexandria Real Estate Equities, a top REIT in life sciences properties, navigates market challenges while positioning for long-term growth in prime locations |
Financial Resilience | Explore ARE's solid financial performance, with Core FFO meeting expectations and a robust balance sheet, despite near-term industry headwinds |
Strategic Development | Delve into Alexandria's 7.0 million square feet development pipeline, with over half pre-leased, showcasing continued demand for high-quality assets |
Market Outlook | Analyst price targets average $130, reflecting optimism for ARE's long-term prospects in the evolving life sciences real estate landscape |
Metrics to compare | ARE | Sector Sector - Average of metrics from a broad group of related Real Estate sector companies | Relationship RelationshipAREPeersSector | |
---|---|---|---|---|
P/E Ratio | −579.2x | 66.4x | 9.0x | |
PEG Ratio | 5.18 | 7.35 | 0.01 | |
Price/Book | 0.7x | 2.6x | 0.9x | |
Price / LTM Sales | 4.0x | 10.3x | 3.9x | |
Upside (Analyst Target) | 25.3% | 6.4% | 12.7% | |
Fair Value Upside | Unlock | −15.4% | 0.2% | Unlock |